Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1979 Jan 15;57(2):53-61.
doi: 10.1007/BF01491335.

[Tangier-disease (author's transl)]

[Article in German]

[Tangier-disease (author's transl)]

[Article in German]
G Assmann. Klin Wochenschr. .

Abstract

Tangier disease is a rare autosomal recessive lipid transport disease characterized by the absence of the usual high density lipoproteins from plasma and cholesteryl ester storage in many organs. 25 cases of Tangier disease have been described so long. The predominant clinical symptoms include tonsilar hypertrophy, splenomegaly and peripheral neuropathy. The cholesteryl ester storage is limited to macrophages, Schwann's cells and intestinal smooth muscle cells. Hypocholest erolemia (less than 80mg/dl), hypertriglyceridemia (greater than 200 mg/dl), and the absence of high density lipoproteins in agarose electrophoresis are the major plasma abnormalities. The protein moiety of normal high density lipoprotein consists of apoprotein A-I and apoprotein A-II. In Tangier disease, serum concentrations of these apoproteins are reduced to less than 1% and 5-10%, respectively. Theories concerning the pathogenesis of Tangier disease are only incomplete and unproved up to now; however, a structural abnormality of apoprotein A-I causing an inability to bind to lipid or other proteins (apoprotein A-II) is consistent with several of the recent biochemical findings. The imbalance of cellular cholesterol metabolism caused by the absence of high density lipoproteins as well as the presumed role of these lipoproteins in cholesterol removal from cells are discussed in this article.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Schweiz Med Wochenschr. 1968 Mar 16;98(11):406-12 - PubMed
    1. J Clin Invest. 1977 Jul;60(1):78-88 - PubMed
    1. Lancet. 1967 Jun 24;1(7504):1341-5 - PubMed
    1. Adv Lipid Res. 1975;13:1-89 - PubMed
    1. J Clin Invest. 1977 Mar;59(3):565-75 - PubMed

Publication types